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Abstract 
Background: The aim of this study was to investigate the effects of a 6‑month treatment with intragastric balloon 
(IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS).
Methods: Fifty patients (aged 18–50 years) with obesity and MS were selected for treatment with IGB for 6 months. 
Body composition was verified with dual‑energy X‑ray absorptiometry (DXA) at baseline and right after IGB removal. 
Anxiety/depressive symptoms were assessed with the Beck Depression Inventory (BDI) and the hospital anxiety and 
depression scale (HADS) at baseline and after 6 months of treatment.
Results: In total, 39 patients completed the study. After 6 months, there were significant decreases in weight 
(11.7 ± 9.6 kg, p < 0.0001) and waist circumference (9.3 ± 8.2 cm, p < 0.0001). Weight loss was also demonstrated 
by DXA and corresponded to decreases of 3.0 ± 3.4% in body fat percentage, 7.53 ± 7.62 kg in total body fat, and 
3.70 ± 4.89 kg in lean body mass (p < 0.001 for all comparisons). Depressive symptoms scores decreased by a mean 
of 4.57 ± 10.6 points when assessed with the BDI (p = 0.002) and 1.82 ± 5.16 points when assessed with the HADS‑
Depression (p = 0.0345). Anxiety symptoms scores decreased by a mean of 1.84 ± 4.04 points when determined with 
the HADS‑anxiety (p = 0.0066). The decrease in body fat percentage was the parameter that best correlated with 
improvements in depressive (p = 0.008) and anxiety symptoms (p = 0.014).
Conclusions: In obese individuals with MS, fat mass reduction was associated with short‑term improvements in 
depressive and anxiety symptoms.
Trial Registration Registered at ClinicalTrials.gov, NCT01598233
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Background
The growing prevalence of obesity is a great concern, 
given the association between this disorder and sev-
eral chronic diseases, including cardiovascular diseases, 
type 2 diabetes, hypertension, and cancer [1]. Obesity, 
depression, and anxiety share overlapping psychosocial 
and pathophysiological etiologies [2–5]. Individuals with 
major depressive or anxiety disorders present dysregu-
lation of the hypothalamic–pituitary–adrenal axis with 
increased levels of stress-related hormones and other 
mediators, favoring food intake and body fat accumula-
tion [2, 3, 6].
Several studies have found controversial results while 
evaluating the association of overweight and obesity 
with mental disorders using body mass index (BMI) [7–
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predictor of mental disorders, with a higher BMI showing 
a stronger association with depression [11]. In contrast 
with these findings, Papelbaum et  al. found no associa-
tion between BMI and depression or anxiety in a sample 
of 212 women seeking treatment for obesity [9]. On the 
other hand, measures of body composition have been 
associated with psychiatric symptoms [13–15]. Cug-
ini et  al. analyzed the association between anxiety and 
depression with body composition, assessed with bio-
electrical impedance. These authors showed that anxiety 
and depression were influenced by relative reductions in 
lean mass and increase in fat mass in obese patients [13]. 
In a recent cross-sectional study, our group has shown 
that the percentage of total body fat—but not central fat, 
BMI, or waist circumference (WC)—was associated with 
an increased severity of anxiety and depressive symptoms 
in obese individuals with metabolic syndrome (MS) [15].
Analyses of the impact of weight loss treatment on 
mental health have demonstrated improvements in psy-
chopathological parameters [16–24]. In a meta-analysis 
of 31 studies, Fabricatore et al. showed that most weight 
loss approaches had favorable effects on mood [16]. A 
recent systematic review analyzed eight studies directly 
evaluating the association between the amount of weight 
loss after behavioral and/or dietary interventions and the 
decrease in depressive symptoms. The results showed 
that only three out of the eight studies reported a sig-
nificant positive relationship between weight loss and the 
degree of improvement in depressive symptoms [22]. A 
recent study reported no differences in depression sever-
ity between depressed and non-depressed morbidly 
obese women after weight loss, reflected by decreases in 
body fat (analyzed by bioelectrical impedance) and BMI, 
following treatment with IGB for 6 months. However, the 
degree of weight loss in the depressed group after treat-
ment was found to have improved the depression status 
[24].
Based on these considerations, the aim of this study 
was to evaluate the association between weight loss and 
changes in body composition evaluated by dual-energy 
X-ray absorptiometry (DXA) with changes in depressive 




This study comprised a consecutive sample of 50 patients 
who sought treatment for obesity and MS and were will-
ing to lose weight. The participants were included after 
fulfilling the eligibility criteria to participate in the study 
and signing a written informed consent form. The proto-
col was approved by the Ethics Committee of the State 
Institute of Diabetes and Endocrinology of Rio de Janeiro, 
where the patients were recruited. The study was regis-
tered at ClinicalTrials.gov (NCT01598233).
The criteria for inclusion in the study comprised age 
between 18 and 50 years, obesity (BMI ≥ 30 kg/m2) and 
the occurrence of MS diagnosed according to the Inter-
national Diabetes Federation (IDF) criteria [25, 26]. The 
exclusion criteria were type 1 or 2 diabetes mellitus, 
pregnancy or desire to become pregnant within 6 months 
from the enrollment, alcoholism, advanced liver disease, 
end-stage renal disease, current or prior coronary artery 
disease (defined as prior myocardial infarction, stable 
or unstable angina, or coronary revascularization), cur-
rent or prior cerebrovascular disease (defined as prior 
ischemic stroke, transient ischemic attack, or carotid 
revascularization), history of a psychiatric disorder, cur-
rent use of antidepressants or other psychiatric medi-
cations, use of antiobesity medications, and weight loss 
treatment in the previous 6 months [15].
Study procedures
At the baseline evaluation (week 0), a silicone IGB (Sil-
imed Silicone, Instrumental Médico Cirúrgico Hospital 
Ltda, Rio de Janeiro, RJ, Brazil) was implanted by upper 
gastrointestinal endoscopy under deep sedation. Under 
endoscopic visualization, the IGB was placed in the 
stomach and filled with 650  mL of normal saline solu-
tion (0.9% NaCl) and 20 mL of methylene blue solution. 
According to local regulations and our institutional eth-
ics committee, all patients remained in the hospital for 
up to 24  h after the procedure. The patients were fol-
lowed up for 6 months when the IGB was then removed 
via endoscopy.
Anthropometric measures
The visits occurred at weeks 0 (baseline), 8, 16, and 24. 
During each visit, the following anthropometric data 
were recorded: body weight (kg), height (m), BMI (weight 
divided by the squared height), and WC (cm; determined 
at the midpoint between the lowest rib and the iliac 
crest).
Evaluation of body composition parameters
Body composition was evaluated at weeks 0 and 24 by 
DXA with the densitometer Prodigy (GE Healthcare, Inc., 
Madison, WI, USA), and included the following analyses: 
body fat content (%), fat distribution, and lean mass (g).
Assessment of anxiety and depressive symptoms
Anxiety and depressive symptoms were assessed with 
the hospital anxiety and depression scale (HADS), a 
self-report instrument to assess anxiety and depressive 
symptoms during the previous week. The items exclude 
somatic symptoms, avoiding overlap between somatic 
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illness and mood disorders. It comprises seven state-
ments relevant to anxiety or depression (HADS-anxiety 
and HADS-depression), in which each response consists 
of a four-point rating scale, with a higher score indicating 
a worse condition [27, 28]. The Beck Depression Inven-
tory (BDI) was also used to measure the severity of the 
depressive symptoms. The instrument comprises 21 
questions, each one with four optional answers. The total 
score is the sum of the scores obtained in each individual 
item [29]. Both questionnaires were applied at all time 
points (weeks 0, 8, 16, and 24).
Statistical analysis
The statistical analysis was performed with GraphPad 
InStat 3.00 for Windows 95 (GraphPad Software, San 
Diego, CA, USA). The mean absolute change in weight, 
BMI, waist, total fat (in grams and percentage) and lean 
mass (in grams), as well as BDI, HADS-depression, and 
HADS-anxiety scores were analyzed from baseline to 
week 24 using Wilcoxon matched pairs test. Spearman’s 
correlation coefficient was used to determine the cor-
relations between improvements in weight and body 
composition parameters and the decrease in psychiatric 
symptoms. The level of statistical significance was set at 
5% (p ≤ 0.05).
Results
Overall, 50 patients were included in the study. The 
cohort had a mean age of 34.6 ±  7.1  years and a mean 
BMI of 40.1 ± 6.3 kg/m2. The BMI was above 40 kg/m2 
in 23 patients (46%) and below this level in 27 individuals 
(54%). During the 6-month follow-up period, the patients 
had a mean weight loss of 11.7 ± 9.6 kg (p < 0.0001), a 
decrease in BMI of 4.4 ±  3.5  kg/m2 (p  <  0.0001), and a 
reduction in WC of 9.3 ±  8.2 cm (p < 0.0001). In total, 
29 (74.35%) patients lost more than 5% of their initial 
weight, while 16 (41.02%) lost more than 10%, and 11 
(28.20%) lost more than 15%. Variations in body com-
position demonstrated by DXA included a total body fat 
decrease of 7.53 ± 7.62 kg (p < 0.0001), corresponding to 
3.0 ± 3.4% (p < 0.001), and a total lean mass decrease of 
3.70 ±  4.89  kg (p  <  0.001). The complete anthropomet-
ric and DXA data results have been previously published 
[30].
Patients who completed the study also displayed sig-
nificant improvements in psychiatric symptoms assessed 
by both psychiatric scales (Table 1; Fig. 1). Symptoms of 
depression decreased by an average of 4.57 ± 10.6 points 
in the BDI (p = 0.002; Fig. 1a) and 1.82 ± 5.16 points in 
the HADS-depression (p = 0.0345; Fig. 1b). Symptoms of 
anxiety decreased by an average of 1.84 ± 4.04 points in 
the HADS-anxiety (p = 0.0066; Fig. 1c).
We used correlation analysis to investigate whether 
weight loss and modifications in body composition influ-
enced the improvements in psychiatric symptoms and 
present the results in Table  2. The absolute decrease in 
the percentage of body fat correlated with improvements 
in BDI scores (p = 0.008; Fig. 2a) and anxiety symptoms 
(p  =  0.014; Fig.  2b). Interestingly, waist loss correlated 
significantly with the improvement in anxiety symptoms 
(p = 0.017), with weight and BMI showing a trend toward 
significance (p = 0.08 for both). 
Discussion
Several studies have reported a positive impact of weight 
loss on mental disorders such as depression and anxiety 
[16–24]. However, the most used parameter of weight 
loss in these analyses was the BMI, which does not reflect 
the individual’s body composition. Among accurate 
methods to measure body composition, DXA has proven 
to be one of the most reliable in clinical practice due to 
its high reproducibility, moderate cost, minimal irradia-
tion, and fast execution [31, 32].
To the best of our knowledge, this is the first study to 
correlate psychiatric symptoms with weight loss and 
changes in body composition assessed by DXA after 
6  months of IGB treatment. In addition to the weight 
loss already expected with IGB, significant improvements 
in depressive and anxiety symptoms were evidenced in 
this specific population. Two additional relevant facts 
were observed using DXA. First, there was no correla-
tion between decreases in weight, BMI, and WC with 
improvement in depressive symptoms. However, the 
decrease in the percentage of total fat correlated with 
the decrease in BDI, but not with changes in the HADS-
depression score. Second, improvements in anxiety 
symptoms correlated with improvements in both WC 
and percentage of total fat.
Different treatment options for obesity, such as behav-
ioral and pharmacological therapies, surgery, and IGB 
have been associated with improvements in mood after 
weight loss [16–24]. Psychological and interpersonal 
Table 1 Patients’ characteristics at baseline and 6 months 
after treatment with intragastric balloon (IGB)
These results refer only to patients who completed the study
Data Median (minimum–maximum)
BDI Beck Depression Inventory; HADS hospital anxiety and depression scale
Baseline (n = 50) 6 months (n = 39) p value
BDI 16 (1–32) 6 (0–45) 0.0019
HADS‑depression 7 (1–14) 4 (0–18) 0.0345
HADS‑anxiety 8 (1–18) 5 (0–20) 0.0066
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changes, such as improvements in negative self-esteem, 
drive for thinness, body dissatisfaction, anxiety, eating 
disorder, personality disorders (borderline, avoidant, pas-
sive-aggressiveness) have been speculated to be directly 
related to weight loss [23, 33]. It is worth noticing that 
significant improvements in depressive symptoms have 
already been observed even with dietetic interventions. 
In 2008, Kiortsis et al. demonstrated significant improve-
ments in the Hamilton Depression Rating Scale (HAM-
D) scores with three different interventions: low-caloric 
diet (LCD), sibutramine  +  LCD, and orlistat  +  LCD 
[34]. In 2009, Faulconbridge et  al. demonstrated that 
four different interventions for weight loss (three groups 
receiving sibutramine and one group receiving lifestyle 
modification alone) led to significant improvements in 
BDI scores [19]. In 2013, Grilo et al. evaluated the effects 
of two different interventions (orlistat  +  a behavioral 
weight loss [BWL] program versus placebo  +  BWL) in 
obese individuals with and without binge eating disorder 
[35]. Although patients treated with orlistat presented 
increased weight loss, similar improvements in depres-
sive symptoms were observed in all groups [35]. These 
studies demonstrate that even mild weight loss, regard-
less of the implemented intervention, is associated with 
significant improvements in depressive symptoms. On 
the other hand, most studies have reported a tendency 
Fig. 1 Effect of 6‑month treatment with IGB in BDI (a*), HADS‑D (b**) and HADS‑A scores (c***). IGB intragastric balloon; BDI Beck Depression Inven‑
tory; HADS hospital anxiety and depression scale; HADS-A hospital anxiety and depression scale‑anxiety; HADS-D hospital anxiety and depression 
scale‑depression; * p = 0.002; ** p = 0.0345; *** p = 0.0066
Table 2 Correlation between  variations in  body composition and  psychiatric symptoms after  intragastric balloon (IGB) 
treatment (∆ for all variables)
DXA dual-energy X-ray absorptiometry; BMI body mass index; BDI Beck Depression Inventory; HADS hospital anxiety and depression scale; HADS-D hospital anxiety 
and depression scale-depression; HADS-A hospital anxiety and depression scale-anxiety
BMI (kg/m2) Weight (kg) Waist (cm) Total fat (g) Total fat (%) Lean mass (g)
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for a decrease and normalization in psychopathological 
symptoms following bariatric surgery [36–40]. However, 
most of these studies have failed to investigate whether 
these improvements were independently associated with 
the degree of weight loss.
The IGB is a therapeutic option for the treatment of 
obesity. In randomized, sham-controlled trials, treatment 
with liquid-filled IGB promoted weight loss through 
different mechanisms, including decreased hunger, 
increased satiety, and modification in eating habits (as a 
self-educational tool) [40–42]. Short-term studies have 
reported weight losses between 12 and 15.2  kg after 
6  months of IGB, and our results are consistent with 
these data [39–45]. A few studies have analyzed the body 
composition after 6  months of IGB using bioelectrical 
impedance, showing a significant reduction in fat mass 
and fat-free mass [24, 46, 47]. Bužga et al. used DXA to 
verify the body composition after treatment with IGB 
and demonstrated sharp decreases in fat and lean mass 
[48]. Our patients also presented similar changes in body 
composition verified by DXA.
As far as we are aware, only one study has investigated 
changes in depressive symptoms after treatment with 
IGB [24]. The authors demonstrated that the improve-
ment in depressive symptoms was closely associated 
with weight loss. However, when depressed patients were 
divided according to BMI (≤40 or >40 kg/m2), neither a 
difference in depression score nor in depression sever-
ity was noted, despite the important difference in body 
weight and, thus, in body image and self-esteem [24]. 
Our patients showed a reduction in BDI scores after 
6 months with the IGB. They also presented a significant 
decrease in all anthropometric measures, so it is possible 
that improvements in self-esteem, perception of corpo-
ral image, and life satisfaction could have been reflected 
in these patients’ depression symptoms. However, the 
inclusion in the BDI of somatic symptoms to evaluate 
depression and well-being attributed to weight loss may 
have influenced this result, as improvements in these 
symptoms could alleviate physical problems related to 
obesity. This fact could explain the relationship between 
the improvement in BDI and the decrease in body fat, but 
does not explain its lack of association with anthropo-
metric variables.
In addition to our findings regarding BDI and body 
composition, we were unable to demonstrate an asso-
ciation between the amount of weight loss and the 
improvement in symptoms of depression with the 
HADS-depression scale. Somatization could partially 
explain this difference; obesity may be considered as 
probably influencing the development and maintenance 
of somatization disorder (i.e., expressions of physical 
complaints with no corresponding organic injuries) [8, 
49]. The HADS has been developed to avoid interfer-
ence from somatic disorders on the scale, so anxiety 
and depression symptoms related with physical diseases 
were excluded [50]. Taken together the results from the 
HADS-depression and BDI, it seems that the improve-
ment in depressive symptoms was not directly related 
to the amount of weight loss, as it occurred in patients 
receiving an effective treatment for obesity, regardless of 
the degree of weight loss.
The decrease in anxiety symptoms assessed with the 
HADS-anxiety after IGB was another finding of our 
study. Unlike the depressive symptoms, the anxiety 
symptoms were directly associated with the decrease 
in WC (with a trend toward significance observed with 
weight and BMI), as well as in total fat mass. One rea-
sonable explanation is that the improvement in anxiety 
symptoms is more related to the weight loss per se than 
the improvement in depressive symptoms, and is inde-
pendent of changes in total fat, visceral fat, or lean mass.
The present study has some limitations. First, we did 
not include a control group and our sample comprised a 
small number of patients. Second, the only inclusion cri-
teria used to define obesity was BMI ≥30 kg/m2. There-
fore, a very heterogenous sample was selected for this 
study, with BMI ranging from 30.9 to 53.7 kg/m2. Third, 
Fig. 2 Correlation between body fat and depressive (a) and anxiety 
symptoms (b) after IGB treatment. IGB Intragastric balloon; BDI Beck 
Depression Inventory; HADS hospital anxiety and depression scale; 
HADS-A hospital anxiety and depression scale‑anxiety
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only 78% of the sample completed the study (39 individu-
als). Eleven patients failed to complete the study due to 
gastric intolerance in four, balloon rupture in five, uterus 
cancer in one, and loss to follow-up in another. It is worth 
noticing that balloon rupture, a rare complication of the 
procedure, occurred in 10% of the sample. Finally, the 
significant number of patients who were unable to toler-
ate the device (8%) indicates that significant gastric intol-
erance may be one of the most important adverse events 
related to the IGB. In contrast, our study had important 
strengths, including the use of DXA to analyze the body 
composition and the adoption of two different question-
naires to evaluate the occurrence of mood disorders.
Conclusions
In conclusion, a 6-month treatment of individuals with 
obesity and MS using IGB was associated with significant 
weight loss and significant improvements in depressive 
and anxiety symptoms. By using DXA, we also demon-
strated that the improvement in psychiatric symptoms 
was associated with the decrease in the percentage of 
body fat, but not with the anthropometric parameters, 
including BMI and WC. Further studies are necessary 
to clarify the role of body fat and weight loss in mental 
health.
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